US equities
|
INTC
$92.07
▲+0.00%
SNDK
$1,330.05
▲+0.00%
MU
$934.27
▲+0.00%
NVDA
$213.66
▲+0.00%
SKHY
$162.09
▲+0.00%
GOOGL
$283.82
▲+0.00%
AMZN
$243.79
▲+0.00%
TSLA
$403.30
▲+0.00%
INTC
$92.07
▲+0.00%
SNDK
$1,330.05
▲+0.00%
MU
$934.27
▲+0.00%
NVDA
$213.66
▲+0.00%
SKHY
$162.09
▲+0.00%
GOOGL
$283.82
▲+0.00%
AMZN
$243.79
▲+0.00%
TSLA
$403.30
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Assembly Biosciences, Inc. - Common Stock
(NQ:
ASMB
)
20.86
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 29, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Assembly Biosciences, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus
October 29, 2026
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026
October 05, 2026
ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference
September 10, 2026
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program
September 08, 2026
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Stock Jumps After Wall Street Says Gilead Opt-In ‘Significantly De-Risks’ Genital Herpes Programs
↗
December 22, 2025
Via
Stocktwits
Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
August 13, 2026
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead
↗
June 08, 2026
Assembly Biosciences (NASDAQ:ASMB) outlined its antiviral and liver disease development strategy during a fireside chat at the 47th Annual Goldman Sachs Healthcare Conference, highlighting upcoming...
Via
MarketBeat
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands
↗
June 05, 2026
Assembly Biosciences (NASDAQ:ASMB) is awaiting a key development plan from partner Gilead Sciences for its herpes simplex virus programs while advancing ABI-6250 into multiple liver disease...
Via
MarketBeat
Assembly Biosciences Announces Upcoming Investor Conference Presentations
May 28, 2026
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
May 26, 2026
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
May 22, 2026
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
May 22, 2026
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference
↗
May 14, 2026
Assembly Biosciences (NASDAQ:ASMB) Chief Medical Officer Anuj Gaggar outlined the company’s virology strategy and upcoming clinical priorities during a Bank of America-hosted discussion, emphasizing...
Via
MarketBeat
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
May 13, 2026
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference
May 11, 2026
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
May 07, 2026
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026
April 09, 2026
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
March 19, 2026
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
December 22, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
Assembly Biosciences Inc (NASDAQ:ASMB) Fits the Minervini Trend Template with Strong Growth Fundamentals
↗
December 15, 2025
Assembly Biosciences (ASMB) exemplifies a high-growth momentum stock, meeting strict technical uptrend criteria and showing accelerating earnings and sales fundamentals.
Via
Chartmill
Assembly Biosciences Inc (NASDAQ:ASMB) Fits the Minervini Trend Template with High Growth Momentum
↗
November 24, 2025
Assembly Biosciences (ASMB) stock meets Mark Minervini's Trend Template with a perfect technical rating, 397% from lows, and accelerating 298% revenue growth.
Via
Chartmill
Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates
November 10, 2025
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®
November 07, 2025
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Forecasting The Future: 4 Analyst Projections For Assembly Biosciences
↗
October 14, 2025
Via
Benzinga
Assembly Biosciences Announces Upcoming Investor Conference Participation
October 14, 2025
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe
October 10, 2025
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals
↗
September 29, 2025
Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action.
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
↗
August 08, 2025
Via
Benzinga
Assembly Biosciences Announces Pricing of $175 Million in Equity Financings
August 08, 2025
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes
August 08, 2025
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
